XOMA Royalty (XOMA) Total Debt (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Total Debt came in at $102.8 million in Q1 2026, down 9.5% year-on-year from $113.6 million in Q1 2025, and down 5.63% quarter-over-quarter from $109.0 million in Q4 2025.
XOMA Royalty (XOMA) Total Debt (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Total Debt across 16 years of filings, most recently posting $102.8 million for Q1 2026.
- Total Debt for Q1 2026 came in at $102.8 million, down 9.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $102.8 million (down 9.5% YoY), and the FY2025 annual result was $109.0 million, down 7.86% from the prior year.
- Total Debt came in at $102.8 million for Q1 2026 at XOMA Royalty, down from $109.0 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $124.1 million in Q4 2023 to a low of $102.8 million in Q1 2026.
- The 4-year median for Total Debt is $115.9 million (2024), against an average of $115.0 million.
- Across the five-year window, Total Debt slipped 4.67% in 2024 and decreased 9.5% in 2026, its largest moves.
- XOMA Royalty's Total Debt stood at $124.1 million in 2023, then retreated by 4.67% to $118.3 million in 2024, then slipped by 7.86% to $109.0 million in 2025, then fell by 5.63% to $102.8 million in 2026.
- The last three Total Debt figures came in at $102.8 million (Q1 2026), $109.0 million (Q4 2025), and $108.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 102.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102.84 Mn |
| Dec 31, 2025 | 108.98 Mn |
| Sep 30, 2025 | 108.73 Mn |
| Jun 30, 2025 | 113.87 Mn |
| Mar 31, 2025 | 113.63 Mn |
| Dec 31, 2024 | 118.27 Mn |
| Sep 30, 2024 | 117.92 Mn |
| Jun 30, 2024 | 120.79 Mn |
| Mar 31, 2024 | 120.67 Mn |
| Dec 31, 2023 | 124.06 Mn |
| Mar 31, 2021 | 18.86 Mn |
| Dec 31, 2020 | 20.85 Mn |
| Sep 30, 2020 | 29.95 Mn |
| Jun 30, 2020 | 31.09 Mn |
| Mar 31, 2020 | 31.53 Mn |
| Dec 31, 2019 | 32.28 Mn |
| Sep 30, 2019 | 32.68 Mn |
| Jun 30, 2019 | 26.02 Mn |
| Mar 31, 2019 | 22.58 Mn |
| Dec 31, 2018 | 22.48 Mn |